Free Trial
NASDAQ:CDT

Conduit Pharmaceuticals 5/14/2024 Earnings Report

Conduit Pharmaceuticals logo
$2.88 +0.37 (+14.74%)
Closing price 04:00 PM Eastern
Extended Trading
$2.82 -0.06 (-2.26%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Conduit Pharmaceuticals EPS Results

Actual EPS
-$75.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Conduit Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conduit Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Conduit Pharmaceuticals Earnings Headlines

Chaotic markets? No worries!
As you may have seen over the last few weeks, I've been giving out special daily setups on my favorite ticker. We’ve been taking these setups @ 10AM and so far, we've posted 28 different payouts … Each of which were delivered at exactly 4PM as the market closed. You see, these setups require zero oversight and have shown the power to deliver in the most chaotic market conditions. And after a few weeks of fine-tuning … I knew it was time to let you in on The 4 PM Payout Plan. That's why Jack Carter and I pulled back the curtain to reveal how we've been able to nail in a 96% win rate in the same window the market lost 11 trillion dollars in value.
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
See More Conduit Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Conduit Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Conduit Pharmaceuticals and other key companies, straight to your email.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals (NASDAQ:CDT), a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

View Conduit Pharmaceuticals Profile

More Earnings Resources from MarketBeat